The efficacy and safety of remimazolam for the management of emergence agitation: a randomized, double-blind, placebo-controlled study.

ABSTRACT:

Introduction

Emergence agitation (EA) is a common postoperative complication characterized by confusion, disorientation, and restless behavior that can lead to self-harm, the removal of medical devices, and other adverse events. This randomized, double-blind, placebo-controlled study was designed to assess the efficacy and safety of a novel benzodiazepine, remimazolam, in the management of EA.

Methods

A total of 219 adults experienced EA (Riker Sedation-Agitation Scale SAS score ≥5) after otolaryngological surgery were randomly assigned (1:1:1 ratio) to receive one of the following three treatments: 2.5 mg remimazolam, 5.0 mg remimazolam, or placebo. The primary endpoint was the treatment success rate of EA, which was defined as an SAS score of <5 within 15 min after adminis

SUBMITTER: Lu X 

PROVIDER: S-EPMC12401913 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature